|
Patent landscape, scope, and claims: |
United States Patent 5,683,677 Scope, Claims, and US Patent Landscape for Medicinal Aerosol Formulations Using 1,1,1,2-Tetrafluoroethane
Executive summary
US 5,683,677 is narrowly focused on a medicinal aerosol formulation where (i) the medicament is fully dissolved, (ii) the propellant is essentially free of chlorofluorocarbons and is based on 1,1,1,2-tetrafluoroethane (HFC-134a), and (iii) the composition is suitable for inhalation. Dependent claims narrow to adding a higher polarity cosolvent (notably ethyl alcohol). The patent’s enforceable scope is therefore tied to solvent-dissolved medicaments in HFC-134a-based CFC-free inhalation aerosols, not to suspension aerosols, blend propellants outside the recited “substantially free” constraint, or non-inhalation delivery.
Core claim coverage
- Claim 1: inhalable medicinal aerosol formulation with fully dissolved medicament in CFC-free propellant comprising HFC-134a.
- Claim 2: Claim 1 + higher polarity additive selected from a specific list, including ethyl alcohol.
- Claim 3: Claim 2 where additive is ethyl alcohol.
What does US 5,683,677 claim 1 cover: medicinal aerosol formulations with HFC-134a and fully dissolved medicaments?
Claim 1 elements (all required for literal infringement)
- A medicinal aerosol formulation suitable for inhalation delivery.
- A therapeutically effective amount of a medicament.
- A propellant that is:
- substantially free of chlorofluorocarbons, and
- comprising 1,1,1,2-tetrafluoroethane (HFC-134a).
- The medicament is fully dissolved in the formulation.
Built-in claim scope boundaries
- “Fully dissolved” excludes formulations where the medicament is present as undissolved particles (suspensions) or has significant particulate fraction that is not dissolved in the continuous phase. For infringement, a defendant typically argues either incomplete dissolution, heterogeneous phase behavior, or formulation structure where medicament is not fully dissolved.
- “Substantially free of chlorofluorocarbons” allows trace impurities but not meaningful levels of CFCs. This creates a formulation design lever: if a competing product uses different propellants or contains detectable CFCs (even if low), the “substantially free” element becomes a factual and regulatory/compositional issue.
- “Propellant comprising HFC-134a” is a “comprising” limitation: it does not exclude additional non-CFC propellant ingredients so long as HFC-134a is present and the composition remains “substantially free” of CFCs. But if the competing formulation avoids HFC-134a entirely, it falls outside the claim.
- Inhalation suitability is a functional attribute. If the formulation is not intended for inhalation (for example, topical sprays), it is outside literal scope even if chemistry overlaps.
Practical infringement mapping
- If an inhalation aerosol product uses HFC-134a as a primary propellant and the active is dissolved (or formulated to be molecularly dissolved) rather than suspended, Claim 1 is the primary capture mechanism.
- If the active is suspended, Claim 1 is weakened by the “fully dissolved” requirement, and the infringement analysis pivots to whether the product meets the dissolution condition under assay or formulation characterization.
Does Claim 1 cover combination propellant systems, or only formulations where HFC-134a is the sole propellant?
Answer based on claim wording
- Claim 1 uses “propellant … comprising 1,1,1,2-tetrafluoroethane,” which is open-ended on additional components.
- The limiting constraint is CFC-free status plus presence of HFC-134a.
- Therefore, Claim 1 can cover blends that include other non-CFC propellants, cosolvents, and excipients, provided the total propellant system remains “substantially free of chlorofluorocarbons” and includes HFC-134a.
But what still falls outside Claim 1
- No HFC-134a present: outside literal scope.
- CFC present above the tolerance implied by “substantially free”: outside literal scope.
- Medicinal aerosol not fully dissolved: outside literal scope.
What does Claim 2 add: higher polarity cosolvents with HFC-134a inhalation aerosols?
Claim 2 depends on Claim 1 and adds:
- At least one compound having higher polarity than HFC-134a
- Selected from: ethyl alcohol, isopropyl alcohol, n-pentane, isopentane, neopentane, and isopropyl myristate
Scope implications
- Claim 2 is narrower than Claim 1 because the formulation must include at least one specified “higher polarity” cosolvent.
- This claim creates strong alignment with common aerosol formulation practice:
- Alcohol cosolvents (ethanol, isopropanol) are frequently used to modify solvency and facilitate dissolution of actives that have limited solubility in fluorinated propellants.
- Isopropyl myristate is a lipophilic ester that can function as a solvating or stabilizing excipient, potentially improving compatibility and dissolution behavior.
Risk and design-around logic
- If a competitor keeps HFC-134a and fully dissolves the active but uses a different cosolvent not in the enumerated list, Claim 2 is not literally met.
- If the formulation uses one of the enumerated compounds but the compound’s polarity relative to HFC-134a is disputed or not established for the relevant formulation context, Claim 2 creates litigation leverage around “higher polarity” characterization. In practice, this becomes an expert-driven factual issue.
What does Claim 3 cover: HFC-134a inhalation aerosols with ethyl alcohol as the higher-polarity compound?
Claim 3 depends on Claim 2 and narrows further to:
- The higher polarity compound is ethyl alcohol.
Scope implications
- Claim 3 is the narrowest literal-coverage hook.
- Products using ethanol as cosolvent with HFC-134a and fully dissolved medicament can be at higher risk for Claim 3-style capture, assuming other elements of Claim 1 are also satisfied (inhalation suitability, CFC-free, fully dissolved).
Design-around
- Substituting ethanol with another allowed compound (isopropanol, isopropyl myristate, etc.) moves the product out of Claim 3 but may still fall within Claim 2.
- Using a non-listed cosolvent can move the product out of Claim 2 and Claim 3 while still potentially risking Claim 1 if the active is fully dissolved in HFC-134a and inhalation delivery is used.
How strong is the patent estate for US 5,683,677 based on its claim structure (formulation-only, solvent criteria, and dependence)?
Claim-strength drivers
- Limited to specific propellant chemistry: HFC-134a presence and “substantially free of chlorofluorocarbons” anchor scope to a particular propellant regime.
- High specificity on dissolution state: “fully dissolved” restricts the class of infringing products.
- Cosolvent lock-in: dependent claims restrict to an explicit list; Claim 3 is further restricted to ethanol.
- Formulation, not use or method of treatment: this is typically easier to enforce against a specific marketed formulation but harder to reach through broad therapeutic indications where other formulation approaches are used.
Most likely infringement scenarios
- A defendant markets an inhalation aerosol where:
- the active is molecularly dissolved in an HFC-134a based formulation, and
- the formulation meets the CFC-free constraint, and
- ethanol (for Claim 3) or another listed polar additive (for Claim 2) is present.
Most likely non-infringement scenarios
- Suspension aerosols, or formulations where active exists as undissolved particulate.
- HFC-134a-free propellant systems.
- Use of non-listed cosolvents (evading Claims 2 and 3) with attention to maintaining full dissolution and inhalation suitability (to preserve Claim 1 exposure).
What generic entry risks exist for products that use HFC-134a inhalation aerosols after US 5,683,677?
Risk profile by formulation design
- High risk (Claim 1–3 potential):
- HFC-134a-containing inhalation aerosol
- active is fully dissolved
- CFC-free
- ethanol cosolvent (Claim 3) or other enumerated higher polarity cosolvent (Claim 2)
- Moderate risk (Claim 1 exposure only):
- HFC-134a-containing, fully dissolved, CFC-free, inhalable
- uses non-listed cosolvent system (avoiding Claim 2 and 3)
- Lower risk (likely outside literal scope):
- HFC-134a excluded
- active not fully dissolved (suspension)
- not inhalation delivery
Litigation posture expectation
- For composition patents with dissolution language, disputes usually center on formulation characterization (solubility, dissolved fraction, phase behavior) and the factual “substantially free” threshold for CFCs.
What patent litigation and FDA pathway facts are relevant to US 5,683,677 enforcement, and what typical positions do parties take?
US 5,683,677 is a formulation composition patent; enforcement and defenses typically track the claim elements:
- Plaintiff positions
- Use of HFC-134a in inhalation aerosol
- demonstrable dissolved-state active ingredient
- CFC-free status consistent with “substantially free”
- ethanol or other listed polar cosolvent presence for dependent claims
- Defendant positions
- active ingredient is not fully dissolved or exists in heterogeneous state
- HFC-134a is absent or replaced by other propellants
- CFC content exceeds “substantially free,” or “chlorofluorocarbons” definition is disputed
- cosolvent not among the enumerated list (for Claim 2/3)
Because the question requests landscape analysis of US 5,683,677 specifically, this response focuses strictly on claim-scope mechanics derived from the provided claims and does not add external litigation data not supplied here.
How does US 5,683,677 compare with other HFC-134a inhalation aerosol patents (formulation vs. device vs. method)?
Comparison frame
- Patents in this space often fall into:
- Propellant system substitutions (CFC to HFC replacement)
- Solvent/cosolvent and stabilization systems
- Particle engineering (for suspensions)
- Delivery device mechanics (valves/nozzles/actuation)
- Method-of-use for indications
Where US 5,683,677 sits
- It is strongest against formulations that meet a specific propellant and dissolution paradigm.
- It is not inherently an indication-use patent; it is not designed to capture every HFC-134a product regardless of whether the active is dissolved.
Competitive implication
- In practice, competitors can often reduce exposure by:
- switching propellants,
- switching to suspension systems,
- and/or using alternative cosolvents not in the enumerated list.
What would the US Orange Book status likely be for this type of formulation patent?
Orange Book listings depend on whether the patent is listed for an approved drug product and whether it meets Orange Book listing criteria (drug substance/active ingredient plus approval linkage).
For US 5,683,677 specifically, this response contains only claim-logic scope derived from the provided text and does not map Orange Book status, because no Orange Book listing data for the patent number is provided.
Timeline: when does patent exclusivity end for US 5,683,677, and how is that calculated?
This response cannot compute exclusivity or expiration dates without the patent’s filing date, issue date context, term adjustments, and any patent term extension information. The user-provided prompt contains only the claims and patent number, not the term-related metadata required for a correct exclusivity timeline.
Key Takeaways
- US 5,683,677 Claim 1 is directed to inhalable aerosol formulations where the medicament is fully dissolved in an HFC-134a-containing propellant that is substantially CFC-free.
- Claim 2 adds a narrow solvency/excipient hook: a higher polarity compound selected from a defined list, including ethanol and isopropanol and specific hydrocarbons/esters.
- Claim 3 is the narrowest: ethanol is the specified higher-polarity compound.
- The claim set is composition-focused with design-around levers: avoid HFC-134a, avoid full dissolution, and avoid the listed cosolvents (ethanol/isopropanol/named hydrocarbons/isopropyl myristate) to reduce risk against dependent claims.
FAQs
-
Do “fully dissolved” language and “medicament” breadth mean any active ingredient is covered?
Claim 1 covers a “medicament” broadly, but infringement still requires the specified solvent state and propellant system.
-
Can a product infringe Claim 1 if it contains HFC-134a plus additional non-CFC propellants?
The claim allows a propellant that “comprises” HFC-134a, constrained by being “substantially free” of CFCs.
-
What is the easiest claim-design workaround: changing propellant or changing cosolvent?
Changing propellant to remove HFC-134a avoids Claim 1. Changing cosolvent may avoid Claims 2 and 3 but not necessarily Claim 1 if dissolution and HFC-134a remain.
-
If a competitor uses ethanol but the medicament is a suspension, does Claim 3 still apply?
Not if the medicament is not “fully dissolved,” because that is a required element of Claim 1 and therefore Claim 3.
-
Could “substantially free of chlorofluorocarbons” be satisfied with trace CFC contamination?
The wording permits some level consistent with “substantially free,” but whether a trace level meets that threshold is factual and depends on measurable composition.
References
- United States Patent 5,683,677, claims 1-3 (provided).
More… ↓
⤷ Start Trial
|
